INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Portfolio Update as at 31 October 2013
|
Total net assets |
£176.0m |
|
NAV per share |
319.5p |
|
Share price |
302.0p |
|
Total value of unquoted investments |
£24.7m |
|
Total number of portfolio companies |
71 |
Top Ten Holdings
|
Company Name |
% NAV |
|
Gilead |
8.9 |
|
Celgene |
8.4 |
|
Amgen |
6.9 |
|
Regeneron |
6.5 |
|
Biogen |
6.0 |
|
Incyte |
4.4 |
|
NPS |
3.9 |
|
Alexion |
3.7 |
|
Aegerion |
3.3 |
|
Pharmacyclics |
3.2 |
|
|
----------- |
|
Total |
55.2 |
|
Trust Characteristics |
% NAV |
|
Profitable |
56 |
|
Becoming Profitable |
14 |
|
Unprofitable |
30 |
|
|
----------- |
|
Total |
100 |
|
Geographical Allocation |
% NAV |
|
United States & Canada |
93 |
|
Europe |
7 |
|
|
----------- |
|
Total |
100 |
|
Quoted/Unquoted allocation |
% NAV |
|
Quoted |
87 |
|
Unquoted |
13 |
|
|
----------- |
|
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
15 NOVEMBER 2013